Clinical Ambiguities—Ongoing Questions

Many factors need to be considered when choosing the mode of delivery of immunoglobulin (IgG) replacement therapy for a given patient with primary immunodeficiency disease (PIDD). Despite some general guidance as provided in the previous discussions, a number of ongoing questions remain. This articl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical immunology 2013, Vol.33 (Suppl 2), p.99-103
Hauptverfasser:	Torgerson, Troy R., Bonagura, Vincent R., Shapiro, Ralph S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedical and Life Sciences Biomedicine Decision Making, Computer-Assisted Drug Administration Routes Guideline Adherence - ethics Humans Immunoglobulins, Intravenous - administration & dosage Immunologic Deficiency Syndromes - epidemiology Immunologic Deficiency Syndromes - immunology Immunologic Deficiency Syndromes - therapy Immunology Infectious Diseases Internal Medicine Medical Microbiology Patient Rights - ethics Practice Guidelines as Topic - standards Practice Patterns, Physicians' - ethics Practice Patterns, Physicians' - standards
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Many factors need to be considered when choosing the mode of delivery of immunoglobulin (IgG) replacement therapy for a given patient with primary immunodeficiency disease (PIDD). Despite some general guidance as provided in the previous discussions, a number of ongoing questions remain. This article attempts to provide some answers and clarification for clinical situations in which the choice of intravenous IgG (IVIG) or subcutaneous IgG (SCIG) may be ambiguous.
ISSN:	0271-9142 1573-2592
DOI:	10.1007/s10875-012-9851-4